How to position for a US invasion of Greenland?

Original Reddit post

Author speculates on portfolio positioning if the US invades Greenland, listing European software/pharma beneficiaries and US industrial losers.

BA — WATCH Author argues a US invasion of Greenland would trigger European sanctions or tariffs that hit US industrial exporters, and Boeing specifically would be hit hard. The position is conditional on that geopolitical event, so it is a watch rather than a current short. No specific downside magnitude or risk is stated.

Oil companies, Boeing, Caterpillar, GE and similar stocks will be hit hard.

CAT — WATCH Author argues a US invasion of Greenland would trigger European sanctions or tariffs that hit US industrial exporters, and Caterpillar specifically would be hit hard. The position is conditional on that geopolitical event, so it is a watch rather than a current short. No specific downside magnitude or risk is stated.

Oil companies, Boeing, Caterpillar, GE and similar stocks will be hit hard.

GE — WATCH Author argues a US invasion of Greenland would trigger European sanctions or tariffs that hit US industrial exporters, and GE specifically would be hit hard. The position is conditional on that geopolitical event, so it is a watch rather than a current short. No specific downside magnitude or risk is stated.

Oil companies, Boeing, Caterpillar, GE and similar stocks will be hit hard.

NOVN.SW — WATCH Author speculates Europe would invest heavily to become independent from US pharmaceuticals, which could benefit European drugmakers like Novartis. The trade is conditional on a US invasion of Greenland scenario. No specific target or risk is provided.

Pharmaceuticals like Pfizer or Eli Lilly will be spared in the short-run but Europe will heavily invest to become independent from the US as well, which could be good for Novartis, Roche, Sanofi, Biontech, Bayer, FMC and the like.

ROG.SW — WATCH Author speculates Europe would invest heavily to become independent from US pharmaceuticals, which could benefit European drugmakers like Roche. The trade is conditional on a US invasion of Greenland scenario. No specific target or risk is provided.

Pharmaceuticals like Pfizer or Eli Lilly will be spared in the short-run but Europe will heavily invest to become independent from the US as well, which could be good for Novartis, Roche, Sanofi, Biontech, Bayer, FMC and the like.

BNTX — WATCH Author speculates Europe would invest heavily to become independent from US pharmaceuticals, which could benefit European drugmakers like BioNTech. The trade is conditional on a US invasion of Greenland scenario. No specific target or risk is provided.

Pharmaceuticals like Pfizer or Eli Lilly will be spared in the short-run but Europe will heavily invest to become independent from the US as well, which could be good for Novartis, Roche, Sanofi, Biontech, Bayer, FMC and the like.

BAYN.DE — WATCH Author speculates Europe would invest heavily to become independent from US pharmaceuticals, which could benefit European drugmakers like Bayer. The trade is conditional on a US invasion of Greenland scenario. No specific target or risk is provided.

Pharmaceuticals like Pfizer or Eli Lilly will be spared in the short-run but Europe will heavily invest to become independent from the US as well, which could be good for Novartis, Roche, Sanofi, Biontech, Bayer, FMC and the like.

SAP.DE — WATCH Author argues Europe will seek to become less dependent on US software and AI, and will rely on successful incumbents like SAP. The trade is conditional on a US invasion of Greenland scenario. No specific target or risk is provided.

In the same vein, Europe will seek to become less dependent on US software / tech and AI. Since European governments will seek fast progress, they will likely rely on successfull incumbents with the necessary talent and infrastructure, like SAP, Atos, Dassault, Siemens, Amadeus and the like.

ATO.PA — WATCH Author argues Europe will seek to become less dependent on US software and AI, and will rely on successful incumbents like Atos. The trade is conditional on a US invasion of Greenland scenario. No specific target or risk is provided.

In the same vein, Europe will seek to become less dependent on US software / tech and AI. Since European governments will seek fast progress, they will likely rely on successfull incumbents with the necessary talent and infrastructure, like SAP, Atos, Dassault, Siemens, Amadeus and the like.

DSY.PA — WATCH Author argues Europe will seek to become less dependent on US software and AI, and will rely on successful incumbents like Dassault Systèmes. The trade is conditional on a US invasion of Greenland scenario. No specific target or risk is provided.

In the same vein, Europe will seek to become less dependent on US software / tech and AI. Since European governments will seek fast progress, they will likely rely on successfull incumbents with the necessary talent and infrastructure, like SAP, Atos, Dassault, Siemens, Amadeus and the like.

SIE.DE — WATCH Author argues Europe will seek to become less dependent on US software and AI, and will rely on successful incumbents like Siemens. The trade is conditional on a US invasion of Greenland scenario. No specific target or risk is provided.

In the same vein, Europe will seek to become less dependent on US software / tech and AI. Since European governments will seek fast progress, they will likely rely on successfull incumbents with the necessary talent and infrastructure, like SAP, Atos, Dassault, Siemens, Amadeus and the like.

Unpriced research observations (excluded from Calls and Returns):

SAN.PA — WATCH Author speculates Europe would invest heavily to become independent from US pharmaceuticals, which could benefit European drugmakers like Sanofi. The trade is conditional on a US invasion of Greenland scenario. No specific target or risk is provided. resolved_entity_name_mismatch

Pharmaceuticals like Pfizer or Eli Lilly will be spared in the short-run but Europe will heavily invest to become independent from the US as well, which could be good for Novartis, Roche, Sanofi, Biontech, Bayer, FMC and the like.